cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Sensei Biotherapeutics Inc
1 own
5 watching
Current Price
$1.39
$-0.04
(-2.8%)
logo-snse
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
42.7M
52-Week High
52-Week High
5.0
52-Week Low
52-Week Low
1.3
Average Volume
Average Volume
0.04M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization42.7M
icon52-Week High5.0
icon52-Week Low1.3
iconAverage Volume0.04M
iconDividend Yield--
iconP/E Ratio--
What does the Sensei Biotherapeutics Inc do?
Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company also develops SNS-101, a monoclonal antibody for the treatment of cancer; and SNS-401-NG, an ImmunoPhage vaccine targeting multiple tumor antigens. It has a collaboration with The University of Washington to research and develop Merkel cell carcinoma vaccine. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
Read More
How much money does Sensei Biotherapeutics Inc make?
News & Events about Sensei Biotherapeutics Inc.
Globe Newswire
27days ago
BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer, today announced a clinical supply agreement with Regeneron for its anti-PD1 therapy Libtayo(...
Ticker Report
1month ago
Citigroup started coverage on shares of Sensei Biotherapeutics (NASDAQ:SNSE Get Rating) in a research report sent to investors on Tuesday , The Fly reports. The brokerage issued a buy rating on the stock. Separately, Oppenheimer upgraded shares of Sensei Biotherapeutics from a market perform...
Business Wire
1month ago
Newman Ferrara LLP announced today that the firm is conducting investigations on behalf of shareholders of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) (Sensei or the Company). The investigations concern whether certain of the Senseis officers and directors breached their fiduciary duties to...
Globe Newswire
1month ago
- Closes Boston research site, reducing workforce by approximately 40 percent to decrease operating expenses - - Continued focus on development of TMAb programs; IND submission for lead antibody SNS-101 anticipated in or prior to April 2023 - - Cash runway extended into the second half of 2025 - ...
Globe Newswire
2 months ago
BOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John Celebi, President and Chief Executive Officer, will participate in...
Frequently Asked Questions
Frequently Asked Questions
What is Sensei Biotherapeutics Inc share price today?
plus_minus_icon
Can Indians buy Sensei Biotherapeutics Inc shares?
plus_minus_icon
How can I buy Sensei Biotherapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Sensei Biotherapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Sensei Biotherapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Sensei Biotherapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Sensei Biotherapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Sensei Biotherapeutics Inc?
plus_minus_icon
What percentage is Sensei Biotherapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Sensei Biotherapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$1.39
$-0.04
(-2.8%)
logo-snse
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00